DNAP.041nice news.(COMTEX) B: DNAPrint Upgrades DNAWitness For Use in the War on Terror ( PR
ewswire-FirstCall )
B: DNAPrint Upgrades DNAWitness For Use in the War on Terror ( PRNewswire-FirstC
ll )
SARASOTA, Fla., Apr 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint
genomics (OTC Bulletin Board: DNAP) of Sarasota, FL announces that the forensics
version of its innovative whole-genome test for individual ancestry admixture
(DNAWITNESS 2.0) has been upgraded for enhanced utility in the international war
on terrorism.
The original DNAWitness(TM) 2.0 test was capable of reporting the percentage of
"European," "western sub-Saharan African," "East Asian" and "Native American"
admixture from a crime scene sample, where the colloquial terms in quotes
represent ancestry traced to four of the major phlyogeographic clades that
constitute the human family tree. The upgraded version of the test,
DNAWitness(TM) 2.5 is capable of doing the same, but in addition can determine
whether a donor of primarily European admixture is of continental European,
Middle Eastern or Indo-Pakistani origin, or whether an East Asian's major ethnic
affiliation is Northern (Chinese/Japanese), Central Asian or South East Asian.
In its ability to effectively resolve between continental European, Middle
Eastern and Indo-Pakistani origin for a crime scene sample, the upgraded
DNAWitness(TM) 2.5 has unprecedented utility for use in the international war on
terrorism.
The DNAWitness(TM) 2.5 genome test is designed to allow forensics investigators
to employ objective science, empiricism and statistical analysis in the
reconstruction of a physical profile or fuzzy photo from DNA left at a crime
scene. DNAPrint has filed both domestic and international PCT patent
applications on many of the most useful markers, database systems and software
algorithms necessary for this purpose. The new technology added to
DNAWitness(TM) makes the product the first scientific instrument ever capable of
measuring within-continent (i.e. ethnic) ancestry by reading across the entire
genome. Prior to the development of DNAWitness(TM) 2.5, a small number of
academic researchers were capable of making inferences on ethnicity from Y and
mtDNA haplogroups, but these sequences reflect merely 2 of the 23 chapters
(chromosomes) in every persons genome and from those short chapters, it is
currently not possible to determine whether the ethnic affiliation of an
individual human being is dominant or minor. Similarly, using CODIS STR (Short
Tandem Repeat) loci, typically used for Forensic identity testing for the
inference of ethnicity is notoriously not reliable and potentially misleading,
since these genetic markers are not Ancestry Informative, and in fact are the
opposite of Ancestry Informative, having been selected from the genome based on
their lack of inter-population diversity. DNAWitness 2.5 has eliminated the
confusion and is very accurate in predicting the genetic heritage of a donor's
DNA.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to develop
genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in
the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint
is developing products in the pharmacogenomic market and has a disease gene
discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under
the ticker symbol: DNAP. For more information about the company, please visit
www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.
Media and Press Contacts
Richard Gabriel
DNAPrint genomics, Inc.
CEO/President
+1-941-366-3400
SOURCE DNAPrint genomics, Inc.
CONTACT: Richard Gabriel, CEO/President of DNAPrint Genomics, Inc., +1
941-366-3400
URL: dnaprint.com
prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved. |
